Phase II study of oral tegafur-uracil and folinic acid as first-line therapy for metastatic colorectal cancer: Taiwan experience

Japanese Journal of Clinical Oncology

Volumn 30, Issue 11, 2000, Pages 510-514

  Lin, Jen Kou ^a   Wang, Wei Shu ^a   Hsieh, Ruey Kuen ^b   Hsu, Tzu Chi ^b   Chiou, Tzeon Jye ^a   Liu, Jin Hwang ^a   Fan, Frank S ^a   Yen, Chueh Chuan ^a   Lin, Tzu Chen ^a   Jiang, Jeng Kae ^a   Yang, Shung Haur ^a   Wang, Huann Sheng ^a   Chen, Po Min ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b MACKAY MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Folinic acid; Metastatic colorectal cancer; Tegafur uracil

Indexed keywords

FOLINIC ACID; TEGAFUR; UFUR; URACIL;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHRODERMA; FEMALE; FOOT DISEASE; GASTROINTESTINAL DISEASE; HAND DISEASE; HEMATOLOGIC DISEASE; HUMAN; MALE; METASTASIS; NEUTROPENIA; PHASE 2 CLINICAL TRIAL;

EID: 0034520548     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/jjco/hyd124     Document Type: Article

References (21)

1. Prognostic factors of advanced colorectal cancer patients
2. A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma
3. A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma
4. 5-Fluorouracil prodrug: Role of anabolic and catabolic pathway modulation in therapy of colorectal cancer
5. A comparative study of oral tegafur and intravenous 5-fluorouracil in patients with metastatic colorectal cancer
6. Oral ftorafur versus intravenous 5-fluorouracil. A comparative study in patients with colorectal cancer
7. Dihydropyrimidine dehydrogenase, kinetic mechanism for reduction of uracil by NADPH
8. Clinical experience with tegafur and low dose oral leucovorin: A dose-finding study
9. Clinical studies of the modulation of ftorafur
10. Fluorinated pyrimidine. A new class of tumor-inhibitory compounds
11. Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil
12. Effects of UFT (mixed compound of tegafur and uracil) on cell kinetics and inhibition of thymidylate synthase in L1210 ascites tumor
13. Anticancer drug distribution in lymph and blood during adjuvant chemotherapy after surgery for gastric cancer
14. A double blind comparative study of tegafur (FT) and UFT (a combination of tegafur and uracil) in advanced breast cancer
15. Effect of coadministration of uracil on the toxicity of tegafur
16. Report on nationwide pooled data and cohort investigation in UFT phase II study
17. Phase II trial of UFT in advanced colon and gastric cancer
18. Uracil-ftorafur: An oral fluoropyrimidine active in colorectal cancer
19. Protracted treatment with UFT and leucovorin by oral way
20. A fixed-ratio combination of uracil and ftorafur (UFT) with low-dose leucovorin. An active oral regimen for advanced colorectal cancer
21. Phase II trial of uracil and tegafur plus oral leucovorin: An effective oral regimen in the treatment of metastatic colorectal carcinoma